SCHEMBL12893333

SCHEMBL12893333

COc1cccc(C2(c3ccc(O)cc3)CCCCC2)c1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.59
ESR2 Q92731 4/20 0.59
KDM1A O60341 1/20 0.47
SLC6A4 P31645 9/20 0.44
SLC6A2 P23975 7/20 0.44
SLC22A1 O15245 3/20 0.44
OPRM1 P35372 3/20 0.44
CHRM2 P08172 1/20 0.44
CHRM1 P11229 1/20 0.44
OPRD1 P41143 1/20 0.44
OPRK1 P41145 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
SLC6A3 Q01959 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22830633 0.98 ESR1 (0.58) ESR1ESR2KDM1ASLC6A4SLC6A2
SCHEMBL12893212 0.89 KDM1A (0.50) KDM1ASLC6A4SLC6A2SLC22A1OPRM1
SCHEMBL8760127 0.84 ESR2 (0.71) ESR1ESR2SLC6A4SLC6A3
SCHEMBL1255410 0.81 GRIN2B (0.44) KDM1ASLC6A4SLC6A2SLC22A1OPRM1
SCHEMBL12893340 0.81 GRIN2B (0.44) KDM1ASLC6A4SLC6A2SLC22A1OPRM1
SCHEMBL27363396 0.81 SLC6A4 (0.43) ESR1ESR2KDM1ASLC6A4SLC6A2
SCHEMBL12893173 0.81 ESR1 (0.71) ESR1ESR2SLC6A4SLC22A1OPRM1
SCHEMBL14531882 0.80 ESR1 (0.65) ESR1ESR2OPRM1OPRD1OPRK1
SCHEMBL12893176 0.80 ESR1 (0.65) ESR1ESR2
SCHEMBL12893170 0.80 ESR1 (0.65) ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822548-B2 Compounds with activity at estrogen receptors ACADIA PHARMACEUTICALS INC. (US) 2014-09-02 US disclosed
US-8822548-B2 Compounds with activity at estrogen receptors ACADIA PHARMACEUTICALS INC. (US) 2014-09-02 US disclosed
US-20110046237-A1 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2011-02-24 US disclosed
US-20110046237-A1 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2011-02-24 US disclosed
US-7825265-B2 di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene ACADIA PHARMACEUTICALS INC. (US) 2010-11-02 US disclosed
US-7825265-B2 di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene ACADIA PHARMACEUTICALS INC. (US) 2010-11-02 US disclosed
WO-2008033894-A2 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2008-03-20 WO disclosed
WO-2007056500-A2 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046237-A1 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ESR2, ESR1, GPER1 ESR1 2/4885ESR2 1/4885KDM1A 2493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.